Hutchmed (China) Limited Director's Share Dealing (4497M)
14 9월 2023 - 5:30PM
UK Regulatory
TIDMHCM
RNS Number : 4497M
Hutchmed (China) Limited
14 September 2023
Director's Share Dealing
Hong Kong, Shanghai & Florham Park, NJ - Thursday, September
14, 2023: HUTCHMED (China) Limited (" HUTCHMED " or the "Company")
(Nasdaq/AIM: HCM; SEHK:13) has received notifications that the
spouse of Mr Graeme Jack, Independent Non-executive Director, sold
a total of 3,000 American Depositary Shares of the Company ("ADSs",
each representing five Ordinary Shares of US$0.10 each of the
Company) at a price of US$14.70 per ADS on September 12, 2023.
Following the above sale of 3,000 ADSs, the holding of Mr Jack
is 17,339 ADSs (Note) , representing approximately 0.01% of the
current issued share capital of the Company.
Note: 17,339 ADSs included (i) 9,128 ADSs currently held by Mr
Jack and (ii) 8,211 ADSs as beneficiary of a trust under long term
incentive plan.
The notifications set out below are provided in accordance with
the requirements of the EU Market Abuse Regulation.
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Ms Debbie Sue Chung
---------------------------------- ---------------------------------------------------------------------------
2 Reason for the notification
---------------------------------------------------------------------------------------------------------------
a) Position/status Spouse of Mr Graeme Jack, Independent Non-executive Director
---------------------------------- ---------------------------------------------------------------------------
b) Initial notification/Amendment Initial notification
---------------------------------- ---------------------------------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
---------------------------------------------------------------------------------------------------------------
a) Name HUTCHMED (China) Limited
---------------------------------- ---------------------------------------------------------------------------
b) LEI 2138006X34YDQ6OBYE79
---------------------------------- ---------------------------------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
---------------------------------------------------------------------------------------------------------------
a) Description of the financial ADS each representing five Ordinary Shares of US$0.10 each
instrument, type of instrument
Identification code
ADS ISIN: US44842L1035
---------------------------------- ---------------------------------------------------------------------------
b) Nature of the transaction Sale of 3,000 ADSs on September 12, 2023 at a price of US$14.70 per ADS.
---------------------------------- ---------------------------------------------------------------------------
Price(s) Volume(s)
----------------------------------- ----------------------------------
US$14.70 3,000 ADSs
----------------------------------- ----------------------------------
c) Price(s) and volume(s)
---------------------------------- ----------------------------------- ----------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 2023-09-12
---------------------------- ----------------------
f) Place of the transaction Nasdaq Stock Market
---------------------------- ----------------------
About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative,
commercial-stage, biopharmaceutical company. It is committed to the
discovery and global development and commercialization of targeted
therapies and immunotherapies for the treatment of cancer and
immunological diseases. It has approximately 5,000 personnel across
all its companies, at the center of which is a team of about 1,800
in oncology/immunology. Since inception, it has focused on bringing
cancer drug candidates from in-house discovery to patients around
the world, with its first three oncology drugs now approved and
marketed in China. For more information, please visit:
www.hutch--med.com or follow us on LinkedIn.
Contacts
Investor Enquiries
Mark Lee, Senior Vice President +852 2121 8200
Annie Cheng, Vice President +1 (973) 306 4490
Media Enquiries
Ben Atwell / Alex Shaw, +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055
FTI Consulting (Mobile)
HUTCHMED@fticonsulting.com
Zhou Yi, +852 9783 6894 (Mobile)
Brunswick HUTCHMED@brunswickgroup.com
Nominated Advisor
Atholl Tweedie / Freddy Crossley / Daphne Zhang,
Panmure Gordon +44 (20) 7886 2500
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHNKQBBOBKKKCD
(END) Dow Jones Newswires
September 14, 2023 04:30 ET (08:30 GMT)
HUTCHMED China (AQSE:HCM.GB)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
HUTCHMED China (AQSE:HCM.GB)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024
